TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of “Buy” from Analysts

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has earned a consensus recommendation of “Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $11.56.

Several equities research analysts have weighed in on TLSI shares. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Canaccord Genuity Group decreased their price target on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences in a research note on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price objective for the company. Lake Street Capital started coverage on shares of TriSalus Life Sciences in a research report on Thursday, February 13th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Roth Mkm restated a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a report on Friday, January 24th.

Insider Buying and Selling

In other TriSalus Life Sciences news, major shareholder Equity Ab Frankenius acquired 62,972 shares of the company’s stock in a transaction dated Tuesday, December 17th. The shares were acquired at an average cost of $3.97 per share, with a total value of $249,998.84. Following the acquisition, the insider now directly owns 6,230,748 shares of the company’s stock, valued at approximately $24,736,069.56. The trade was a 1.02 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO James Emmett Young acquired 6,000 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was acquired at an average price of $5.65 per share, for a total transaction of $33,900.00. Following the purchase, the chief financial officer now directly owns 30,000 shares of the company’s stock, valued at approximately $169,500. This trade represents a 25.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 117,828 shares of company stock worth $544,607 in the last 90 days. Insiders own 32.80% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its stake in shares of TriSalus Life Sciences by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 204,137 shares of the company’s stock worth $1,023,000 after buying an additional 3,710 shares during the last quarter. Bank of America Corp DE boosted its position in TriSalus Life Sciences by 120,471.6% in the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company’s stock worth $894,000 after purchasing an additional 178,298 shares in the last quarter. Bridgeway Capital Management LLC grew its stake in shares of TriSalus Life Sciences by 333.3% during the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company’s stock worth $326,000 after purchasing an additional 50,000 shares during the period. MSD Partners L.P. purchased a new position in shares of TriSalus Life Sciences during the 3rd quarter valued at approximately $184,000. Finally, Northern Trust Corp lifted its stake in shares of TriSalus Life Sciences by 22.7% in the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock valued at $161,000 after purchasing an additional 5,936 shares during the period. Hedge funds and other institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ:TLSI opened at $5.67 on Friday. The firm has a market cap of $172.90 million, a price-to-earnings ratio of -2.28 and a beta of 0.51. The firm has a fifty day moving average price of $5.15 and a 200 day moving average price of $4.74. TriSalus Life Sciences has a fifty-two week low of $3.50 and a fifty-two week high of $10.42.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.